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The immunoproteasome, having been linked to
neurodegenerative diseases and hematological
cancers, has been shown to play an important
role in MHC class I antigen presentation. How-
ever, its other pathophysiological functions
are still not very well understood. This can be
attributed mainly to a lack of appropriate mo-
lecular probes that can selectively modulate
the immunoproteasome catalytic subunits.
Herein, we report the development of molecular
probes that selectively inhibit the major cata-
lytic subunit, LMP2, of the immunoproteasome.
We show that these compounds irreversibly
modify the LMP2 subunit with high specificity.
Importantly, LMP2-rich cancer cells compared
to LMP2-deficient cancer cells are more sensi-
tive to growth inhibition by the LMP2-specific
inhibitor, implicating an important role of
LMP2 in regulating cell growth of malignant
tumors that highly express LMP2.
INTRODUCTION
In the era of proteomics, temporal and spatial control of
protein functions, which are often difficult with conven-
tional genetic manipulations, are critical to the under-
standing of the dynamics of cellular processes. While tra-
ditional genetic approaches have provided useful insight
into the functions of proteins, they are limited by the pos-
sibility that some phenotypes may be due to compensa-
tory responses that occur during development. In addi-
tion, the inhibition of the target gene function is often
irreparable, and thus the desired protein deficiency can-
not be readily regulated, making it difficult to dissect the
precise roles of gene products. One way to complement
classical genetic approaches is to use small molecules
that selectively modulate protein functions. This small-
molecule approach has increasingly contributed to further
our understanding of biological processes.
The proteasome has emerged as amajor player in many
important signaling processes, such as cell cycle progres-
sion [1], inflammatory responses [2], and development [3].Chemistry & Biology 14,Typically, more than 80%of cellular proteins are degraded
by the ubiquitin-proteasome system. The ubiquitin-
proteasome pathway is a highly regulated process in
which proteins are first targeted for degradation by conju-
gation to ubiquitin, a 76 amino acid polypeptide. Ubiquiti-
nated proteins are, in turn, recognized by the 19S regula-
tory domain of the constitutive 26S proteasome. Through
a series of ATP hydrolysis-dependent processes, deubi-
quitinated proteins are threaded into the core proteolytic
complex, the 20S proteasome, where they are degraded
into small peptides. The 20S core has a four-ring stacked
structure with seven different subunits in each ring. The
two inner rings each contain three catalytically active
b subunits. The noncatalytic outer a rings form a gated
channel for unfolded protein entry and a base for the
19S regulatory complexes, which provide the specificity
of the polypeptide recognition.
The 20S catalytic core proteasome has been shown to
exhibit three major activities: a chymotrypsin-like (CT-L)
activity that cleaves after large hydrophobic residues,
a trypsin-like (T-L) activity that hydrolyzes after basic
amino acids, and a caspase-like (C-L) activity that cleaves
after acidic amino acids. Twoother less-characterized cat-
alytic activities have also been ascribed to the protea-
some: BrAAP, which cleaves after branched-chain amino
acids, and SNAAP, which cleaves after small, neutral
amino acids. Althoughmost efforts are directed to develop
proteasome inhibitors against CT-L activity, a few studies
have also been successful in designing compounds that
inhibit other proteasomal activities, such as C-L [4] and
T-L activity-specific inhibitors [5–8].While theCT-L activity
of the proteasome has been suggested to be largely re-
sponsible for the proteolytic function of the proteasome
in vivo and in vitro [9, 10], the contribution of theothermajor
activities remains to be determined. In recent years, re-
searchers have been investigating the functions of the dif-
ferent proteolytic activities in cancer cells byusinga variety
of proteasome inhibitors [10, 11]. Regarding clinical appli-
cations of proteasome inhibitors, bortezomib (VELCADE),
a broad-spectrum proteasome inhibitor targeting both the
constitutive proteasome and immunoproteasomes, was
recently approved by the FDA for the treatment of multiple
myeloma (MM) [12]. However, its clinical use is severely
limited due to drug-related toxicities [13].
In higher vertebrates, exposure of cells to stimuli, such
as interferon (IFN)-g or tumor necrosis factor (TNF)-a,419–430, April 2007 ª2007 Elsevier Ltd All rights reserved 419
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ketone Linear Peptide Natural Product
Epoxomicin and Dihydroeponemycin
Tripeptide epoxyketones with a linear hydro-
carbon chain at the P3 position have higher
specificity toward immunoproteasome cata-
lytic subunits than normal tetrapeptide epoxy-
ketones such as epoxomicin.induces the synthesis of certain catalytic subunits (LMP7,
LMP2, andMECL-1), which replace the constitutive b sub-
units X, Y, and Z, respectively, and form an alternative pro-
teasome form known as the immunoproteasome [14]. The
immunoproteasome, as compared to the constitutive (or
regular) proteasome, has an enhanced capacity to gener-
ate peptides bearing hydrophobic and basic amino acids
at their C termini and a reduced capacity to produce pep-
tides bearing acidic residues at their C termini [15]. Conse-
quently, the spectrum of the resultant peptides is shifted
toward peptides that associate with MHC class I mole-
cules with increased affinity [16]. While the immunopro-
teasome is suggested to play a major role in MHC class
I antigen presentation, it is believed not to be solely re-
sponsible for antigen presentation, as the constitutive pro-
teasome also generates immunogenic epitopes [17].
In recent years, questions regarding the role of the
immunoproteasome in cells from nonimmune systems
have arisen due to the findings in which expression levels
of individual immunoproteasome subunits are correlated
with pathological processes, such as hematological can-
cers and neurodegenerative diseases [18–20]. For in-
stance, a high level of immunoproteasome catalytic sub-
units has been detected in neurodegenerative human
brains [21, 22], which is known to be an immunologically
privileged organ [23]. Specifically, the LMP2 catalytic sub-
unit is more highly expressed in the brains of Alzheimer’s
disease (AD) patients than in the brains of nondemented
elderly, whereas its expression in young brains is negligi-
ble or absent [24]. More recently, it has been shown that
LMP2 is required for estrogen receptor-mediated gene
transcription and for estrogen-stimulated cell cycle pro-
gression [25]. Further, some studies indicated that the im-
munoproteasome and its catalytic subunits may be in-
volved in Huntington’s disease (HD) neurodegeneration
[21]. MM is also known to express a high level of immuno-
proteasome subunits due to the bone marrow microenvi-
ronment where it replicates [26–29]. Based on these ob-
servations, an intriguing hypothesis has been proposed
that the specific inhibition of the immunoproteasome sub-
units may induce selective apoptosis of MM cells while420 Chemistry & Biology 14, 419–430, April 2007 ª2007 Elseviesparing other cells lacking or minimally expressing immu-
noproteasome subunits [30], making them an attractive
investigative target for clinical applications.
Despite the potential role of the immunoproteasome
catalytic subunits in pathogenesis, their functions are still
not fully understood. In addition, the catalytic activities of
individual immunoproteasome subunits are not clearly
characterized. The major problem that limits further un-
derstanding of immunoproteasome biology is the lack of
appropriate molecular probes that selectively target the
immunoproteasome catalytic subunits. Unfortunately,
the proteasome inhibitors developed to date either prefer-
entially target the constitutive proteasome subunits or fail
to exhibit appropriate specificity toward the immunopro-
teasome subunits.
With this in mind, our ongoing efforts are aimed at the
design and synthesis of small-molecule probes that selec-
tively target the immunoproteasome catalytic subunits.
While the sequence comparison of catalytic subunits
from the constitutive proteasome and immunoprotea-
somes exhibits a high level of homology, structural infor-
mation about the active sites of the immunoproteasome
subunits remains to be elucidated, complicating our
efforts toward the design of immunoproteasome sub-
unit-specific probes via a rational target-based design
strategy.
Two natural product proteasome inhibitors, epoxomicin
and eponemycin (Figure 1), are members of the a0,b0-
epoxyketone linear peptide family [31, 32]. It has been
previously shown that, despite structural similarities,
epoxomicin (1) and dihydroeponemycin (2), an active
derivative of eponemycin, differ considerably in their
proteasome subunit binding specificity [31, 32]. For exam-
ple, dihydroeponemycin labels the catalytic threonine
residues of the immunoproteasome subunits LMP2 and
LMP7 and the constitutive proteasome subunit X. On
the other hand, epoxomicin covalently modifies the N-
terminal catalytic threonine residues of the constitutive
proteasome (X and Z) and immunoproteasome (LMP7
and MECL1) subunits. We have previously shown that
a relatively higher specificity of dihydroeponemycinr Ltd All rights reserved
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LMP7), as compared to epoxomicin, is due to a linear hy-
drocarbon residue at the N terminus (i.e., isooctanoic
group) [33]. In addition, it has been suggested that amino
acid residues at the P10-P20 sites (see Figure 1) of immuno-
proteasome substrates may also play an important role in
immunoproteasome specificity [34]. We have also previ-
ously reported that serine at the P2 site of dihydroepone-
mycin can be replaced with alanine while maintaining the
subunit-binding pattern of dihydroeponemycin [35].
Based on these observations, we would like to develop
a new molecular probe that will selectively inactivate the
catalytic threonine residue of immunoproteasome subunit
LMP2 by derivatizing the P10-OH group of dihydroepone-
mycin (Figure 1). We envision that LMP2 inhibitors that
covalently modify the catalytic threonine residue of
LMP2 will provide a valuable chemical genetic tool in the
functional exploration of individual immunoproteasome
subunits. Herein, we report the syntheses, through the
use of easily available protecting groups, of a variety of
P10-derivatized dihydroeponemycin analogs. We also
show that certain P10 derivatives of dihydroeponemycin
irreversibly inactivate the LMP2 subunit with remarkable
specificity in living cells. Finally, we show that LMP2-rich
cancer cells are more sensitive to growth-inhibitory
activity of the LMP2 inhibitor compared to LMP2-deficient
cancer cells.
RESULTS AND DISCUSSION
Development of a Screening Assay
for LMP2-Specific Compounds
Biotin-tagged epoxomicin and dihydroeponemycin [35]
were used as assay probes with which to perform
a screening assay for LMP2-specific compounds. We first
corroborated the screening assay bywestern blot analysis
with epoxomicin (1) and dihydroeponemycin (2), protea-
some subunit-binding patterns of which have been previ-
ously well defined [31, 35]. The EL4 cell system was cho-
sen because these cells express high levels of catalytic
subunits of both the constitutive proteasome and immu-
noproteasomes. Specifically, various concentrations of
these compounds were preincubated in EL4 cells at
37C for 30min. Assay probes, biotin-tagged dihydroepo-
nemycin or epoxomicin, were then added. Cells were in-
cubated for an additional hour at 37C before cell lysis.
Whole-cell lysates were then analyzed by using 12%
SDS-PAGE and were transferred to PVDF membranes.
Proteins that were newly biotinylated by assay probes
were visualized by using streptavidin-horseradish peroxi-
dase (HRP) and the enhanced chemiluminescence (ECL)
detection system.
As shown in Figure 2, most of the proteasome subunit
bands, which were covalently modified and visualized by
using assay probes, were easily competed away with ex-
cess dihydroeponemycin, its P2 analog, or epoxomicin.
This result confirms that neither epoxomicin nor dihydro-
eponemycin have specificity toward subunits of either
the constitutive proteasome (X) or the immunoproteasomeChemistry & Biology 14,(LMP2 and LMP7). Dihydroeponemycin [Ser / Ala], in
which theP2serine of thedihydroeponemycin analog is re-
placed with alanine, displayed a similar subunit-binding
pattern to that of dihydroeponemycin. Using a similar com-
petition assay,we screenedP10 derivatives of dihydroepo-
nemycin for LMP2-specific compounds. Our expectation
was that preincubation of a LMP2-specific inhibitor in
EL4 cells will result in the modification of the threonine
catalytic residue of the LMP2 subunit, preventing further
modification of the occupied LMP2 subunit by assay
probes. Therefore, the preoccupied LMP2 will no longer
be visualized onwestern blot. However, proteasome cata-
lytic subunits that are not targeted by the LMP2 inhibitor
will be covalently labeled by the assay probes and visual-
ized by western blotting by using the HRP-ECL system.
Screening Compounds that Selectively Target LMP2
in EL4 Cells
Since a linear hydrocarbon group at the P3 position is
shown to provide high specificity toward the LMP2 sub-
unit [33], the heptanoic group was positioned at the P3
site of dihydroeponemycin (Figure 1). We then focused
on the derivatization at the P10-OH group (Figure 3). First,
we added an easily available methoxymethyl ether (MOM)
group, preparing compounds 11 and 14. This replacement
caused a dramatic loss in the potency and specificity
compared to dihydroeponemycin (Figure 4A). Similarly,
compounds with a bulky tert-butyldiphenylsilyl (TBDPS)
group (10) or tetrahydropyranyl (THP) group (13) also
resulted in loss of subunit-binding activity against the
immunoproteasome (Figure 4A).
Strikingly, when the MOM group was replaced with
a methoxyethoxymethyl (MEM) ether group (12), high
Figure 2. A Competition Assay to Test the Proteasome Sub-
unit Binding Specificity of Proteasome Inhibitors
(A) LMP7 and X as well as LMP2 protein bands are competed away by
dihydroeponemycin (2) or its analog (9) on western blot.
(B) Proteasome subunit (LMP7/X) bands are efficiently competed away
by excess epoxomicin or dihydroeponemycin on western blot. EL4
cells were preincubated with proteasome inhibitors for 30 min before
being treated with assay probes (biotin-epoxomicin or biotin-dihy-
droeponemycin). After 1 hr of incubation, cells were lysed and ana-
lyzed by western blot by using streptavidin-HRP and ECL.419–430, April 2007 ª2007 Elsevier Ltd All rights reserved 421
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Reagents and conditions for 12. (a) 2-Methoxyethoxymethyl Chloride, i-Pr2EtN, CH2Cl2, 0
C/ rt; (b) Benzonitrile, H2O2, i-Pr2EtN, MeOH, 0C, 3 hr;
(c) 5, TFA, CH2Cl2, 30 min; (d) HBTU, HoBt, i-Pr2EtN, CH2Cl2, rt, 12 hr; (e) TBAF, THF, 1 hr. *(e) precedes (d): 7a was deprotected with TBAF before it
was coupled to 7.specificity toward LMP2 was observed (Figure 4B). When
a tert-butyldimethylsilyl (TBDMS) group was attached at
the C-terminal hydroxyl group (15), an even higher speci-
ficity toward the LMP2 subunit was obtained, as shown in
Figure 4B. Preincubation of EL4 cells with 1 mMcompound
15 was sufficient to covalently modify all of the LMP2
subunit in EL4 cells, preventing further modification of
the LMP2 subunit by assay probe. This resulted in selec-
tive attenuation of the LMP2 protein band on the western
blot. Experiments with another assay probe (biotin-
epoxomicin) (Figure 4C), which covalently labels protea-
some subunits LMP7, X, MECL-1, and Z, exhibit no
competition, further supporting the conclusion that both
compounds 12 and 15 selectively target the LMP2 sub-
unit, but not other proteasome subunits.422 Chemistry & Biology 14, 419–430, April 2007 ª2007 ElseviTo demonstrate that compound 15 covalently and
selectively modifies the LMP2 subunit, but not other
subunits, we investigated the mobility shift of the LMP2-
15 adduct by using EL4 cells (Figure 4D). After EL4 cells
were incubated with compound 15 or assay probes (bioti-
nylated epoxomicin [Biotin-EPX] andBiotin-EPN) for 1.5 hr
at 37C, cells were lysed. Whole-cell proteins were then
analyzed by western blot with anti-LMP2, anti-LMP7,
anti-X, and anti-Y antibodies. In this experiment, biotiny-
lated epoxomicin (Biotin-EPX) and biotinylated dihydro-
eponemycin (Biotin-EPN) were used as mobility shift
controls since they have been shown to cause mobility
shift via covalent modification of LMP2 [31, 32, 36].
Due to increasedmolecular weights (by 828.08 for biotin-
epoxomicin and 1078.45 for biotin-dihydroeponemycin),er Ltd All rights reserved
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(A–C) EL4 cells were preincubated with compounds before the treatment of assay probes for visualization of proteasome subunits that are not tar-
geted by compounds 12 and 15. (A) Compounds 10, 11, and 13 nonselectively target proteasome subunits, whereas compound 14 does not bind
proteasome subunits. (B) Compounds 12 and 15 selectively target the immunoproteasome subunit LMP2. (C) Compounds 12 and 15 do not target
other catalytic subunits (LMP7, X, Z, and MECL1).
(D) Cells were incubated for 1 hr before SDS-PAGE and western blot analysis with anti-LMP7, X, and Y antibodies. Compound 15 covalently modifies
the immunoproteasome subunit LMP2, but not other subunits in EL4 cells.
Biotin-EPN, Biotinylated dihydroeponemycin; Biotin-EPX, Biotinylated epoxomicin.assay probe-LMP2 adducts displayed a slower mobility
shift when compared to free LMP2 (lanes 1–3, Figure 4D).
While a mobility shift for the LMP2-15 adduct on SDS-
PAGE was clearly shown in comparison to free LMP2
(lanes 4–6, Figure 4D), it was observed to be slower than
that of assay probe-LMP2 adducts (lanes 2–3 versus lanesChemistry & Biology 14, 44–6). This can be explained with the lower molecular
weight of compound 15 (484.76) as compared to the as-
say probes. While 1 mM compound 15, but not the assay
probes, was sufficient to modify most of the LMP2 sub-
units in cells (lanes 2–3 versus 4–6), no mobility shift was
observed in other proteasome subunits, indicating that19–430, April 2007 ª2007 Elsevier Ltd All rights reserved 423
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with high efficiency.
Compound 15 Blocks Chymotrypsin-like Activity
of the LMP2 Subunit but Has No Effect on the
Activity of the Constitutive Proteasome
in an Angiogenesis Cell Model
The elucidation of protein function, especially with regard
to multiprotein complexes, is clearly one of the important
goals of the small-molecule approach to cell biology. With
respect to the proteasomal complex, researchers have
long been interested in assigning specific catalytic activi-
ties to each b subunit of the proteasome. Based on data
obtained from X-ray analysis and direct inhibition of pro-
teasome activities with a variety of proteasome inhibitors,
all three b subunits of the constitutive proteasome have
been assigned to three different activities [4, 9, 37, 38].
Whereas LMP7 and MECL1 of the immunoproteasome
are shown to possess CT-L and T-L activities, respec-
tively, a clear assignment for the LMP2 subunit of the im-
munoproteasome has not yet been made. LMP2, which
replaces the constitutive proteasome catalytic subunit Y
that is responsible for C-L activity, has been suggested
to cleave substrates after hydrophobic amino acid resi-
dues to generate peptides favored for MHC class I pre-
sentation [39, 40], but experimental data to support this
assumption are lacking. Therefore, with our LMP2-
specific inhibitor in hand, wewanted to determine whether
LMP2 is responsible for CT-L activity. To test this, we used
the natural product lactacystin, which primarily binds the
LMP7 (and MECL1) subunit [41] and inactivates its cata-
lytic activity [42, 43], and then determined whether free
LMP2 has CT-L activity. It should be noted that MECL1
is reported to be responsible for T-L activity [44, 45]. As
shown in Figure 5A, when the immunoproteasome was
preincubated with lactacystin at the concentration at
which 95% of the CT-L activity of the constitutive protea-
some is inhibited, 20% of the CT-L activity of the immu-
noproteasome was blocked compared to control. Simi-
larly, when the immunoproteasome was preincubated
with compound 15 at the concentration at which only
LMP2 is inactivated (see Figures 4D and 6D), 20% of
the CT-L activity of the immunoproteasome was also in-
hibited (Figure 5A). In the presence of both lactacystin
and compound 15, 45% of the CT-L activity was
blocked, whereas the CT-L activity of the immunoprotea-
some was completely blocked when the concentration of
either lactacystin or compound 15 was increased (data
not shown). This finding indicates that these compounds
have an additive inhibitory action on the CT-L enzymatic
function of the immunoproteasome. Collectively, these re-
sults suggest that LMP2 is, at least in part, responsible for
the CT-L activity of the immunoproteasome.
Despite the fact that compound 15 selectively modifies
the catalytic LMP2 subunit and inhibits the CT-L activity of
the immunoproteasome, it is still unclear whether com-
pound 15 also inhibits essential CT-L activity of the consti-
tutive proteasome in living cells. Thus, we next tested
whether compound 15 can disrupt cellular events that424 Chemistry & Biology 14, 419–430, April 2007 ª2007 Elseviare regulated by the constitutive proteasome. Angiogenic
growth of blood vessels requires normal activities of the
constitutive proteasome and is highly sensitive to protea-
some inhibitors [46] such as epoxomicin and dihydroepo-
nemycin. Conversely, endothelial cells do not normally
express the immunoproteasome (data not shown), and,
thus, we expect that angiogenic sprouting in an in vitro
model will be highly sensitive to regular proteasome inhib-
itors, but not to LMP2-specific inhibitors.
The three-dimensional endothelial cell sprouting assay
(3D-ECSA) is an in vitro experimental system that closely
mimics the in vivo angiogenesis processes, featuring the
differentiation of endothelial cells into sprouting structures
within a 3Dmatrix of fibrin or collagen I [47]. We employed
the 3D-ECSA assay to investigate whether compound 15
and proteasome inhibitors differ in their inhibitory activity
on growth factor-induced sprouting angiogenesis. As
anticipated, epoxomicin [2] and dihydroeponemycin
potently inhibited sprouting morphogenesis due to inhibi-
tion of the essential constitutive proteasome activity
(Figure 5B). On the other hand, compound 15 did not
inhibit endothelial sprouting at doses much higher than
those of dihydroeponemycin or epoxomicin, even though
compound 15 is more efficient at inactivating the LMP2
subunit (see Figure 4D). Quantitativemeasurements of en-
dothelial sprouting as described earlier [46, 48] revealed
that compound 15 with concentration as high as 10 mM
only marginally disrupts sprouting (80-fold higher con-
centration than dihydroeponemycin) (data not shown).
Similarly, compound 12 did not inhibit endothelial sprout-
ing. These angiogenesis assay results indicate that the
LMP2 inhibitors do not perturb the functions of the consti-
tutive proteasome in living cells.
LMP2-Specific Inhibitors Selectively and Covalently
Inactivate the LMP2 Subunit in PC3 Prostate
Cancer Cells
Given that one of our goals is to explore the pathophysio-
logical functions of LMP2 in relevant disease models, we
questioned whether LMP2 inhibitors developed here
have any impact on normal biological processes of cancer
cells that predominantly express LMP2. First, we investi-
gated which prostate cancer cells constitutively express
the LMP2 subunit. Surprisingly, among the prostate can-
cer cell lines examined, only androgen-independent PC3
prostate cancer cells, but not androgen-dependent
LNCaP or LN3 cells, constitutively expressed the immuno-
proteasome catalytic subunit LMP2 (Figure 6A). Remark-
ably, the specificity of compounds 15 and 12 toward
LMP2 is even more evident in PC3 cells compared to
EL4 cells. As shown in Figure 6B, the LMP2 protein
band in PC3 cells was selectively attenuated by the
LMP2 inactivators 15 and 12, indicating their high speci-
ficity toward the LMP2 subunit. Unlike epoxomicin or dihy-
droeponemycin, compounds 12 and 15 did not compete
with the biotinylated probes for binding of LMP7, X, Z,
and MECL1 (Figure 6C). Mobility shift assays with western
blot, which is analyzed with anti-LMP2, -LMP7, -X, or -Y
antibodies, clearly showed that compound 15 covalentlyer Ltd All rights reserved
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(A) Inhibition of chymotrypsin-like activity of the immunoproteasomes by compound 15. Proteasome kinetic studies were performed with purified
immunoproteasome. Purified immunoproteasome was preincubated with lactacystin, compound 15, or cotreatment for 30 min before CT-L fluoro-
genic substrate was added (Suc-Leu-Leu-Val-Tyr-AMC). Data were collected over a 1.5 hr period at room temperature. For compound 15, Kobs/[I]
(M1S1) = 83 ± 27. The range of inhibitor concentrations used was 5–20 mM.
(B) Compounds 15 and 12 do not inhibit the constitutive proteasome. Human endothelial cell spheroids were seeded in collagen I gels in a 96-well
plate and were stimulated with vascular endothelial growth factor (VEGF; 20 ng/ml) to induce angiogenic sprouting. In replicate wells, VEGF-treated
spheroids were coincubated with epoxomicin (Epox), dihydroeponemycin (Epn), compound 15, or compound 12. Representative photographic
images of spheroids taken after 24 hr show invasive growth of vessel structures with VEGF alone and compound 15 cotreatment or compound
12 cotreatment, but a potent inhibitory effect with dihydroeponemycin (0.2 mM and 0.5 mM) or epoxomicin (0.2 mM) cotreatment.inactivates LMP2, but not the other catalytic subunits of
proteasomes (Figure 6D). Similar to the results obtained
from the mobility shift experiments with EL4 cells
(Figure 4D), compound 15was a more potent LMP2 inhib-
itor than the biotinylated probes. Probe-LMP2 conjugates
at 1 mMconcentration were not even observed in thewest-
ern blot experiments (lanes 2 and 3 in Figure 6D). LMP7, X,
and Y subunits were not covalently modified by com-
pound 15 even at 10 mM concentration. These results
clearly indicate that compound 15 selectively modifies
LMP2 constitutively expressed in PC3 prostate cancer
cells.Chemistry & Biology 14, 4LMP2-Rich PC3 Prostate Cancer Cells Are More
Sensitive to Growth-Inhibitory Activity
of the LMP2-Specific Inhibitor than
LMP2-Deficient Prostate Cancer Cells
Next, we wished to determine whether the LMP2-specific
inhibitor has effects on the proliferation of PC3 cancer
cells that highly express LMP2. Given that LMP2 is amajor
catalytic subunit of the immunoproteasome and the fact
that proteasomes play an important role in cell growth,
we hypothesized that PC3 cells may be more sensitive
to the LMP2 inhibitor 15 compared to LMP2-deficient
LN3 prostate cancer cells. In contrast, we expect that19–430, April 2007 ª2007 Elsevier Ltd All rights reserved 425
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Chemical Genetic Tools for Proteasome BiologyFigure 6. Selective Modification of the LMP2 Subunit in PC3 Prostate Cancer Cells
(A) LMP2 expression levels of prostate cancer cells.
(B and C) PC3 cells were preincubated with compounds before the treatment of biotinylated dihydroeponemycin to visualize biotinylated proteasome
subunits that are not targeted by compounds 12 and 15. (B) Compounds 12 and 15 selectively target the immunoproteasome subunit LMP2 in PC3
prostate cancer cells. (C) Compounds 12 and 15 do not compete with epoxomicin or dihydroeponemycin for binding Z, MECL1, LMP7, and X sub-
units.
(D) Compound 15 covalently modifies the immunoproteasome subunit LMP2 in PC3 prostate cancer cells. Cells were incubated with compound 15,
biotin-epoxomicin, or biotin-dihydroeponemycin for 1.5 hr. The mobility shift of the LMP2 subunit was analyzed by western blotting with anti-LMP2
antibody.
DPN, dihydroeponemycin; EPX, epoxomicin.the broadly acting proteasome inhibitors epoxomicin and
dihydroeponemycin will not display differential activity
toward the prostate cancer cells regardless of their ex-
pression level of LMP2.We tested this hypothesis bymea-
suring IC50 values for compound 15 in both PC3 (LMP2-
positive) and LN3 (LMP2-deficient) cells. Remarkably,
PC3 cells are about 7-fold more sensitive to the LMP2
inhibitor 15 than LN3 prostate cancer cells (Table 1). In426 Chemistry & Biology 14, 419–430, April 2007 ª2007 Elseviecontrast, both PC3 and LN3 cells were similarly sensitive
to the broad-spectrum proteasome inhibitors epoxomicin
and dihydroeponemycin.
Although it is currently not clear why PC3 cancer cells,
but not other prostate cancer cell lines, constitutively ex-
press LMP2, these results indicate that LMP2 may play
an important role in proliferation of cancer cells that con-
stitutively express LMP2. It is also not known whetherr Ltd All rights reserved
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is a pharmacological target of compound 15. Although it is
presumed that newly synthesized LMP2 (pre-LMP2) is
catalytically inactive until it has matured into catalytically
active LMP2 by LMP7 and has been assembled into the
immunoproteasome [49–51], the possibility of alternative
maturation into a catalytically active LMP2 monomer
that may be functionally important in cell proliferation can-
not be ruled out. Regardless, the high sensitivity of LMP2-
rich PC3 cancer cells to compound 15 suggests that
LMP2 may be a target for therapeutic intervention in
cancers that constitutively express this protein. Addition-
ally, these findings have allowed us to conclude that com-
pound 15may be amolecular probe of LMP2 function that
can be exploited to illuminate the biological roles of its
substrates in immunoproteasome-dependent processes.
In conclusion, we have developed an epoxyketone-
pharmacophore-based LMP2-specific probe with which
the physiological roles of LMP2 in cells can be investi-
gated. As the LMP2 inhibitor blocks proliferation of
LMP2-rich cancer cells with high specificity, it can now
be utilized to determine whether the LMP2 subunit is
a valid target for therapeutic intervention in animal models
of cancer. Further, compound 15 can also be used as
a chemical knockout reagent of LMP2 to screen for immu-
noproteasome substrates that are distinct from regular
proteasome substrates, which will ultimately enhance
our understanding of the role of LMP2 in pathogenic
diseases.
SIGNIFICANCE
The immunoproteasome catalytic subunits have been
implicated in a number of disease states. For example,
they have been suggested as potential new drug dis-
covery targets for the treatment of multiple myeloma.
However, there are currently no immunoproteasome
catalytic subunit-specific inhibitors that can be used
to validate these subunits as therapeutic targets. Fur-
thermore, the exact role of the immunoproteasome
Table 1. Trypan Blue Exclusion Assays Were
Performed by Counting Cell Numbers after 48 hr of
Incubation with Compound 15 or the Random
Proteasome Inhibitors Dihydroeponemycin
and Epoxomicin
IC50 (mM)
a Relative Sensitivityb
Cell line LN3 PC3 -
LMP2 expression No Yes -
15 14.34 2.04 7
Dihydroeponemycin 0.49 0.36 1
Epoxomicin 0.015 0.009 1
a Experiments were repeated at least three times or more.
b Relative sensitivity of LMP2-positive PC3 cells to inhibitors
compared to the LMP2-deficient LN3 cell line = IC50
LN3/
IC50
PC3.Chemistry & Biology 14catalytic subunits in pathogenesis is not clearly under-
stood. Thus, the development of the immunoprotea-
some catalytic subunit LMP2-specific inhibitors
described in this report may not only hold great poten-
tial as a therapeutic agent for certain diseases, but can
also provide a valuable chemical genetic probe to in-
vestigate immunoproteasome biology.
EXPERIMENTAL PROCEDURES
General Remark
Unless otherwise stated, all reactions were carried out under nitrogen
with dry, freshly distilled solvents, oven-dried glassware, andmagnetic
stirring. All solvents were reagent grade. Tetrahydrofuran (THF) was
distilled from sodium/benzophenone. Methylene chloride (CH2Cl2)
was distilled from calcium hydride. Diethyl ether anhydrous was pur-
chased from EMD Chemicals and was used without further purifica-
tion. All reagents were purchased from Sigma-Aldrich and were used
without further purification. All reactions were monitored by thin-layer
chromatography (TLC) by using E. Merk 60F254 precoated silica gel
plates. Flash column chromatography was performed by using E.
Merk silica gel 60 (particle size 0.040–0.063 mm) and was performed
with the indicated solvents. 1Hwas recorded inCDCl3 by using a Varian
300MHz spectrometer at ambient temperature with an internal deute-
rium lock unless stated otherwise. Chemical shifts are referenced to
residual chloroform (d = 7.27 ppm for 1H). High- and low-resolution
mass spectra were carried out by the University of Kentucky Mass
Spectrometry Facility.
Synthesis of 12 is described here as the representative synthetic
procedure for dihydroeponemycin analogs.
(4S)-4-(tert-Butoxycarbonyl)-Amino-2-Hydroxy-Methyl-
6-Methylhept-1-En-3-One, 3
Synthetic procedures were performed as previously reported [11].
(4S)-4-(tert-Butoxycarbonyl)-Amino-2-(Methoxy-
Ethoxymethoxymethyl)-6-Methylhept-1-En-3-One, 4
Methoxyethoxymethyl chloride (0.24 ml, 2.1 mmol) and diisopropyle-
thylamine (0.37 ml, 2.1 mmol) were added to a solution of 3 (114 mg,
0.42 mmol) in CH2Cl2 (5 ml) at 0
C. After stirring at room temperature
for 3 hr, the resulting mixture was poured into ice water (20 ml) and
extracted with CH2Cl2 (33 20 ml). The organic layers were combined,
washed with brine (20 ml), dried with Na2SO4, filtered, and concen-
trated under reduced pressure. The product was then subjected
to flash column chromatography (5:1 hexane:EtOAc), yielding 4
(101 mg, 67%) as a yellowish oil. 1H NMR: d = 6.20 (d, 2J = 31.8 Hz,
2H, 1-H), 5.12 (d, 2J = 9.0 Hz, 1H, NH), 5.03 (m, 1H, 4-H), 4.75 (s,
2H, 2-OCH2O), 4.28 (s, 2H, 2-CH2), 3.69 (m, 2H, 2-OCH2CH2O), 3.55
(m, 2H, 2-OCH2CH2O), 3.38 (s, 3H, 2-OCH3), 1.74 (m, 1H, 6-H), 1.50
(m, 1H, 5-Ha), 1.41 (s, 9H, HBoc), 1.31 (m, 1H, 5-H
b), 0.99 (d, 3J =
6.6 Hz, 3H, CH3CHCH3), 0.90 (d,
3J = 6.6 Hz, 3H, CH3CHCH3) ppm.
(2RS,4S)-4-(tert-Butoxycarbonyl)-Amino-2-(Methoxy-
Ethoxymethoxymethyl)-6-Methyl-1,2-Oxiranyl-Heptane,
5 and 6
Benzonitrile (0.29 ml, 2.8 mmol), H2O2 (0.40 ml, 50% solution in H2O,
7.0 mmol), and diisopropylethylamine (0.5 ml, 2.8 mmol) were added
to a solution of 4 (100 mg, 0.28 mmol) in MeOH (5 ml) at 0C. The re-
action was stirred at 0C for 3 hr. The resulting mixture was then con-
centrated under reduced pressured and was subjected to flash col-
umn chromatography (10:1 hexane:EtOAc) to yield 5 and 6 at a ratio
of 3:1 (60 mg, 60%). 5: 1H NMR: d = 4.82 (d, 2J = 8.4 Hz, 1H, NH),
4.71 (s, 2H, 2-OCH2O), 4.39 (d,
2J = 11.4 Hz, 1H, 2-CHa2), 4.32 (m,
1H, 4-H), 3.68 (m, 2H, 2-OCH2CH2O), 3.57 (m, 2H, 2-OCH2CH2O),
3.49 (d, 2J = 11.4 Hz, 1H, 2-CHb2), 3.40 (s, 3H, 2-OCH3), 3.27 (d,
2J =
4.8 Hz, 1H, 1-Ha), 3.03 (d, 2J = 4.8 Hz, 1H, 1-Hb), 1.75 (m, 1H, 6-H),, 419–430, April 2007 ª2007 Elsevier Ltd All rights reserved 427
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b), 0.97 (d, 3J =
6.6 Hz, 3H, CH3CHCH3), 0.94 (d,
3J = 6.6 Hz, 3H, CH3CHCH3) ppm.
(S)-O-tert-Butyldiphenylsiloxymethyl-N-Heptanoyl-Serine, 7
Lithium hydroxide (91 mg, 3.8 mmol) was added to a solution of
(S)-O-tert-butyldiphenyl-siloxymethyl-N-heptanoyl-seryl methyl ester
(890 mg, 1.8 mmol) in a methanol:water (3:1) solution. The reaction
was stirred at 5C for 15 hr. The resulting mixture was poured into
H2O with cold 1 N HCl and was extracted with CH2Cl2. The organic
layers were combined, washed with brine, dried under Na2SO4, fil-
tered, concentrated, and dried under high vacuum. The product
obtained yielded 7 as a yellowish oil. 1H NMR: d = 7.61 (m, 4H,
Ar-H), 7.41 (m, 6H, Ar-H), 6.24 (d, 2J = 7.5 Hz, 1H, NH), 4.69 (m, 1H,
2-H), 4.17 (dd, 2J = 10.4 Hz, 2J = 3.6 Hz, 1H, 3-Ha), 3.89 (dd, 2J =
10.4 Hz, 2J = 3.6 Hz, 1H, 3-Hb), 2.20 (t, 3J = 7.5 Hz, 2H, 20-H), 1.60
(m, 2H, HHep), 1.29 (m, 6H, HHep), 1.05 (s, 9H, Hbutyl), 0.88 (t,
3J =
6.9 Hz, 3H, 70-CH3) ppm.
(S)-O-tert-Butyldiphenylsiloxymethyl-N-Heptanoyl-Seryl
Methyl Ester
tert-butyldiphenylsilyl chloride (1.95 ml, 7.6 mmol) and imidazole
(519 mg, 7.6 mmol) were added to a solution of (S)-N-heptanoyl-serine
methyl ester (588.6 mg, 2.5 mmol) in CH2Cl2 (20 ml), and the solution
was stirred overnight at room temperature. The resulting mixture was
concentrated under reduced pressure and was subjected to column
chromatography (5:1 hexane:EtOAc), yielding (S)-O-tert-butyldiphe-
nylsiloxymethyl-N-heptanoyl-serylmethyl ester (890mg, 74%)asacol-
orless oil. 1H NMR: d = 7.59 (m, 4H, Ar-H), 7.41 (m, 6H, Ar-H), 6.28 (d,
2J = 8.4 Hz, 1H, NH), 4.70 (m, 1H, 2-H), 4.12 (dd, 2J = 10.1 Hz, 2J =
3.0 Hz, 1H, 3- Ha), 3.89 (dd, 2J = 10.1 Hz, 2J = 3.0 Hz, 1H, 3-Hb), 3.74
(s, 3H, 1-OCH3), 2.11 (t,
3J = 7.7 Hz, 2H, 20-H), 1.57 (m, 2H, HHep), 1.30
(m, 6H, HHep), 1.04 (s, 9H, Hbutyl), 0.88 (t,
3J = 6.7 Hz, 3H, 70-CH3) ppm.
(S)-N-Heptanoyl-Serine Methyl Ester
HBTU (1.83 g, 4.8 mmol), HOBt (0.74 g, 4.8 mmol), and lastly diisopro-
pylethylamine (2.8 ml, 16 mmol) were added to a solution of heptanoic
acid (0.46 ml, 3.2 mmol) and H-Ser-OCH3 (0.5 g, 3.2 mmol) in CH2Cl2
(15 ml). The reaction was stirred overnight at room temperature. The
resulting mixture was subjected to flash column chromatography
(1:2 hexane:EtOAc), yielding (S)-N-heptanoyl-serine methyl ester
(588.6 mg, 79%) as a yellowish oil. 1H NMR: d = 6.47 (b, 1H, NH),
4.69 (m, 1H, 2-H), 3.94 (m, 2H, 3-H), 3.79 (s, 3H, 1-OCH3), 2.27
(t, 3J = 7.6 Hz, 2H, 20-H), 1.63 (m, 2H, HHep), 1.29 (m, 6H, HHep), 0.88
(m, 3H, 70- CH3) ppm.
(4S)-2-Methoxyethoxy-Methoxymethyl-4-([S]-O-tert-
Butyldiphenylsiloxy-Methyl-N-Heptanoylseryl-Amino)-
6-Methyl-1,2-Oxiranyl-Heptane
Trifluoroacetic acid (100 ml, 0.87 mmol) was added to a solution of 5
(45 mg, 0.12 mmol) in CH2Cl2 (0.5 ml) at room temperature for
30 min. Subsequently, the concentrated mixture was dried under
high vacuum to remove trifluoroacetic acid. The resulting crude prod-
uct, 6 (33 mg, ca. 100%), was then used in the following coupling re-
action without further purification. HBTU (68 mg, 0.17 mmol), HOBt
(27 mg, 0.17 mmol), and lastly diisopropylethylamine (104 ml,
0.59 mmol) were added to a solution of 6 (33 mg, 0.12 mmol) and 7
(65 mg, 0.14 mmol) in CH2Cl2 (5 ml). The reaction was stirred overnight
at room temperature. The resulting mixture was subjected to flash
column chromatography (3:1 hexane:EtOAc) to give (4S)-2-methox-
yethoxy-methoxymethyl-4-([S]-O-tert-butyldiphenylsiloxy-methyl-N-
heptanoylseryl-amino)-6-methyl-1,2-oxiranyl-heptane (36 mg, 42%).
1H NMR: d = 7.71 (m, 4H, Ar-H), 7.44 (m, 6H, Ar-H), 7.02 (d, 2J =
8.4 Hz, 1H, 4-NH), 6.17 (d, 2J = 6.6 Hz, 1H, 20-NH), 4.72 (s, 2H, 2-
OCH2O), 4.60 (m, 2H, 4-H, 2
0-H), 4.42 (d, 2J = 11.4 Hz, 1H, 2-CHa2),
4.03 (m, 1H, 30-Ha), 3.70 (m, 3H, 30-CHb2, 2-OCH2CH2O), 3.55 (m,
2H, 2-OCH2CH2O), 3.52 (d,
2J = 11.4 Hz, 1H, 2-CHb2), 3.40 (s, 3H,
2-OCH3), 3.29 (d,
2J = 5.4 Hz, 1H, 1-Ha), 3.04 (d, 2J = 4.8 Hz, 1H,
1-Hb), 2.13 (t, 3J = 7.6 Hz, 2H, 200-H), 1.63 (m, 4H, 6-H, 5-Ha, HHep),428 Chemistry & Biology 14, 419–430, April 2007 ª2007 Elsev1.26 (m, 6H, HHep), 1.07 (s, 9H, 3
0-tBu), 0.96 (d, 3J = 6.3 Hz, 3H,
CH3CHCH3), 0.91 (d,
3J = 6.3 Hz, 3H, CH3CHCH3), 0.86 (t,
3J =
7.6 Hz, 3H, 700- CH3) ppm.
(4S)-2-Methoxyethoxymethoxymethyl-4-N-
Heptanoylserylamino-6-Methyl-1,2-Oxiranylheptane, 12
Tetrabutylammonium fluoride (50 ml, 1 M in THF, 0.05 mmol) was
added to a solution of (4S)-2-methoxyethoxy-methoxymethyl-4-([S]-
O-tert-butyldiphenylsiloxy-methyl-N-heptanoylseryl-amino)-6-methyl-
1,2-oxiranyl-heptane (30 mg, 0.042 mmol) in THF (1 ml). The reaction
was stirred at room temperature for 1 hr, followedby flash columnchro-
matography (1:2 hexane:EtOAc), yielding 12 (16 mg, 80%) as a yellow-
ish oil. 1H NMR: d = 6.83 (d, 2J = 7.5 Hz, 1H, 4-NH), 6.44 (d, 2J = 7.5 Hz,
1H, 20-NH), 4.71 (s, 2H, 2-OCH2O), 4.50 (m, 2H, 4-H, 20-H), 4.41 (d,
2J =
11.7 Hz, 1H, 2-CHa2), 4.08 (m, 1H, 3
0-Ha2), 3.68 (m, 2H, 2-OCH2CH2O),
3.55 (m, 3H, 2-OCH2CH2O, 3
0-Hb2), 3.46 (d,
2J = 11.7 Hz, 1H, 2-CHb2),
3.40 (s, 3H, 2-OCH3), 3.27 (d,
2J= 5.1 Hz, 1H, 1-Ha), 3.05 (d, 2J = 4.8 Hz,
1H, 1-Hb), 2.22 (m, 2H, 200-H), 1.60 (m, 4H, 6-H, 5-Ha, HHep), 1.28 (m, 6H,
HHep), 0.96 (d,
3J = 3.9 Hz, 3H, CH3CHCH3), 0.94 (d,
3J = 3.9 Hz, 3H,
CH3CHCH3), 0.88 (t,
3J = 6.7 Hz, 3H, 700- CH3) ppm. MS (ESI): m/z =
475, calcd. for C23H42N2O8: m/z = 474.59.
Cell Culture and Screening Assay
Murine lymphoma EL4 cells and prostate cancer PC3 cells (ATCC)
were grown in RPMI medium (GIBCO-BRL) supplemented with 10%
fetal bovine serum and 1% penicillin and streptomycin at 37C in
a 5% CO2 incubator. Cells were pretreated with 1 mM biotinylated
compounds 30 min prior to the addition of increasing concentrations
of either dihydroeponemycin, epoxomicin, or dihydroeponemycin an-
alogs as indicated. The cells were then incubated for an additional
hour. Cell lysates were analyzed by 12% SDS-PAGE and were trans-
ferred to PVDF membranes. Proteins that were covalently modified
by biotinylated compounds were visualized with enhanced chemilumi-
nescence by using streptavidin-conjugated horseradish peroxidase
(Sigma-Aldrich) or anti-LMP2 (Affinity BioReagents) and Biomax
X-ray film (Kodak).
Enzyme Kinetic Studies
k association valueswere determined as follows. Inhibitors weremixed
with a fluorogenic peptide substrate and assay buffer (20 mM Tris
[pH 8.0], 0.5 mM EDTA, and 0.035% SDS) in a 96-well plate. The chy-
motrypsin-like activity was assayed by using the fluorogenic peptide
substrates Suc-Leu-Leu-Val-Tyr-AMC (Sigma-Aldrich). Hydrolysis
was initiated by the addition of bovine 20S proteasome or immunopro-
teasome (Biomol International), and the reaction was followed by fluo-
rescence (360 nm excitation/460 nm detection) by using a Microplate
Fluorescence Reader (FL600; Bio-Tek Instruments, Inc., Winooski, VT)
employing the software KC4 v.2.5 (Bio-Tek Instruments, Inc.). Reac-
tions were allowed to proceed for 60–90 min, and fluorescence data
were collected every 1 min. Fluorescence was quantified as arbitrary
units, and progression curves were plotted for each reaction as a func-
tion of time. kobserved/[I] values were obtained by using the PRISM pro-
gram by nonlinear least-squares fit of the data to the following
equation: fluorescence= vst+ ð½v0  vs =kobservedÞð1 exp½kobserved t Þ ,
where v0 and vs are the initial and final velocities, respectively, and
kobserved is the reaction rate constant. The range of inhibitor concentra-
tions tested was chosen so that several half-lives could be observed
during the course of the measurement. Reactions were performed
with inhibitor concentrations that were < 100-fold of those of the pro-
teasome assayed.
3D-Endothelial Cell Sprouting Assay, 3D-ECSA
Endothelial cell spheroids were generated from human umbilical vein
endothelial cells (HUVECs; Cascade Biologicals, Portland, OR) as de-
scribed [48]. The spheroids (4–6/well) were distributed in 96-well plates
in collagen Imatrix for the 3D-ECSA. Cell culturemediumwas added to
each well along with 20 ng/ml VEGF in the presence and absence of
the individual inhibitor. The 3D cultures were incubated in tissueier Ltd All rights reserved
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spheroids were obtained with the 103 objective of a Nikon TE2000
microscope. Sprouting was quantified from digital images according
to our previously published method [46].
Trypan Blue Exclusion Assay
Prostate cancer PC3 and LN3 cells were seeded in 12-well plates.
They were then incubated at 37C until they were 70% confluent be-
fore the appropriate inhibitors were added as indicated in increasing
concentrations. Cells were treated for 48 hr. Viable cells were counted
on a hemocytometer in 0.2% trypan blue solution (Sigma-Aldrich). IC50
values were calculated from sigmoid dose-response curves by the
method of nonlinear regression to a logarithmic function. These data
represent the average of three or more experiments.
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